NYR are the only drug in the world going through phase 1 for both traumatic brain injury and stroke associated brain injury. Once safety is completed the company will have access to whatever money they need to take this through phase 2 including significant non dilutive funding which will be discussed by the CEO this week. AGN has already proved up the mechanism of action we just need to prove safety right now and that’s coming up in the period ahead
AGN - 110 million market cap on safety clearance on phase 1 NYR - 6 million market cap and now going through safety clearance.
The upside is exponential for a very unique drug molecule which comes in varies formulations, cheap to make and wide range of storage conditions allowing for easy access for multiple industries prone to secondary brain injury
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)